Immune co-stimulatory and adjuvant pathways (Fms-related tyrosine kinase 3 ligand, CD40 ligand, Granulocyte-macrophage colony-stimulating factor, and CD80) (FLT3L/CD40L/GM-CSF/CD80)

The immune co-stimulatory and adjuvant pathways involving Fms-related tyrosine kinase 3 ligand (FLT3L), CD40 ligand (CD40L), Granulocyte-macrophage colony-stimulating factor (GM-CSF), and CD80 represent a multi-component therapeutic strategy designed to orchestrate a robust anti-tumor immune response. FLT3L and GM-CSF act as potent recruitment and differentiation factors for dendritic cells (DCs), which are essential for capturing and presenting tumor antigens to the adaptive immune system (UniProt P49771, P04141). Once DCs are recruited to the tumor microenvironment, CD40L and CD80 provide the necessary maturation and co-stimulatory signals to convert these cells into highly efficient activators of T-cells (UniProt P29965, P33681). Specifically, CD40L interacts with CD40 to induce cytokine secretion and MHC upregulation, while CD80 binds to CD28 on T-cells to provide the 'second signal' required for full activation and proliferation. This synergistic approach is frequently utilized in 'in situ' vaccination and gene therapy protocols to overcome the immunosuppressive nature of the tumor microenvironment and induce systemic, long-lasting immunity. Clinically, these pathways are targeted through the administration of recombinant proteins like Sargramostim and CDX-301, or via viral and mRNA vectors that express these ligands directly within the tumor.

Other names

Fms-related tyrosine kinase 3 ligand (FLT3L)CD40 ligand (CD40L/CD154)Granulocyte-macrophage colony-stimulating factor (GM-CSF)B7-1 (CD80)TNFSF5CSF2CD154

Synergistic recruitment, maturation, and activation of antigen-presenting cells (APCs) to enhance T-cell mediated anti-tumor immunity.